Cholesterol
Also known as: Hypercholesterolemia, Hyperlipidemia, Hyperlipoproteinemia, Intravenous
Methodology & AI Transparency ⓘ
Cholesterol Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What is cholesterol? Cholesterol is a waxy, fat-like substance that's found in all the cells in your body.
- 2 Real-world patient consensus: Diagnostic registry E78.5: Cholesterol is managed within Cholesterol & Lipids (aka Hypercholesterolemia).
- 3 Typical cash cost range: Differential triage of Cholesterol (E78.5) utilizes coronary calcium risk in Cholesterol (E78.5: scoring).
- 4 Top reported side effects / signs: Follow-up benchmark in Cholesterol: maintaining LDL Cholesterol [Cholesterol E78.5] within < 85 mg/dL (E78.5).
Ask our AI Specialists anything about Cholesterol
What Is Cholesterol?
What is cholesterol? Cholesterol is a waxy, fat-like substance that's found in all the cells in your body. Your body needs some cholesterol to make hormones , vitamin D , and substances that help you digest foods. Your body makes all the cholesterol it needs. Cholesterol is also found in foods from animal sources, such as egg yolks, meat, and cheese. If you have too much cholesterol in your blood, it can combine with other substances in the blood to form plaque. Plaque sticks to the walls of your arteries. This buildup of plaque is known as atherosclerosis .
Pathophysiology, Underlying Causes & Clinical Presentation
Tissue-level etiology in Cholesterol (E78.5) features remnant cholesterol accumulation [Cholesterol E78.5]. Cross-referenced with NIH MeSH (Cholesterol, Hypercholesterolemia), therapeutic stabilization in cholesterol & lipids is verified against Fasting Triglycerides [Cholesterol E78.5].
Common Symptoms & Clinical Signs
- • Lack of physical activity , with lots of sitting and little exercise. This lowers your HDL (good) cholesterol
- • Smoking , which lowers HDL cholesterol, especially in women. It also raises your LDL cholesterol
- • Presentation of Cholesterol (E78.5): elevated triglyceride-to-HDL ratio [Cholesterol E78.5]
- • Secondary Cholesterol clinical sign: premature family history in Cholesterol (E78.5: of coronary stenting,)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Cholesterol Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | E78.5 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Cholesterol, Triglycerides & Lipids | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: LDL Cholesterol [Cholesterol E78.5] | < 85 mg/dL (E78.5) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fasting Triglycerides [Cholesterol E78.5] | < 100 mg/dL (E78.5) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Lipoprotein(a) [Lp(a)] [Cholesterol E78.5] | < 75 nmol/L (E78.5) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Cholesterol
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Zetia (Ezetimibe) Zetia • RxCUI 349556-B78206178 | Dietary Cholesterol Absorption Inhibitor | 82% | $13.9369 | $ 6.38 /mo |
| Pitavastatin Livalo • RxCUI 861643 | HMG-CoA Reductase Inhibitor | 81% | $0.8365 | $ 20.04 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Cholesterol)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Inclisiran for the Treatment of high: What a 3,660-Participant Study Found In conclusions, in patients with high cholesterol, inclisiran decreased LDL level by 51% without significant adverse effects. The American journal of cardiology • 2020-11-01 • Meta-Analysis | N = 3,660 | 99/100 | PMID 32892993 ↗ |
| New Insights on Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes and high: What a 1,229-Participant Study Found Ezetimibe/simvastatin provided additional lipid-modifying benefits over atorvastatin single-drug treatment at the recommended usual starting and next highest doses in patients with type 2 diabetes. Mayo Clinic proceedings • 2006-12-15 • Randomized Controlled Trial | N = 1,229 | 96/100 | PMID 17165637 ↗ |
| New Insights on Benefits and safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed high: What a 1,148-Participant Study Found The significant reductions of atherogenic lipids including LDL-C, non-HDL-C, and apolipoprotein B seen with evolocumab are similar in patients with and without mixed high cholesterol. Cardiovascular drugs and therapy • 2016-06-15 • Phase III Randomized Trial | N = 1,148 | 96/100 | PMID 27240673 ↗ |
| New Insights on Metabolic and heart and blood vessel effects of TX-001HR in menopausal women with: What a 1,835-Participant Study Found One episode of deep venous thrombosis and three cases of heart and blood vessel disease were observed, similar to expected rates of these events in the general population. Climacteric : the journal of the International Menopause Society • 2019-12-15 • Randomized Controlled Trial | N = 1,835 | 96/100 | PMID 31364889 ↗ |
| New Insights on Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus: What a 2,959-Participant Study Found Ezetimibe/simvastatin was more effective than rosuvastatin in LDL-C lowering, and provided greater or comparable improvements in other lipid measures and hsCRP at the approved usual starting, next highest, and maximum doses in... Current medical research and opinion • 2006-10-15 • Randomized Controlled Trial | N = 2,959 | 96/100 | PMID 17022864 ↗ |
Cholesterol Patient Community & “People Like Me” Threads
Filter Cholesterol community threads and patient logs by age, biological sex, dosage, and treatment duration.